A Possible Role for Chromium(III) in Genotoxicity

by Elizabeth T. Snow*

Chromium is found in the environment in two major forms: reduced Cr(III) and Cr(VI), or chromate. Chromate, the most biologically active species, is readily taken up by living cells and reduced intracellularly, via reactive intermediates, to stable Cr(III) species. Cr(III), the most abundant form of chromium in the environment, does not readily cross cell membranes and is relatively inactive in vivo. However, intracellular Cr(III) can react slowly with both nucleic acids and proteins and can be genotoxic. We have investigated the genotoxicity of Cr(III) in vitro using a DNA replication assay and in vivo by CaCl2-mediated transfection of chromium-treated DNA into Escherichia coli. When DNA replication was measured on a Cr(III)-treated template using purified DNA polymerases (either bacterial or mammalian), both the rate of DNA replication and the amount of incorporation per polymerase binding event (processivity) were greatly increased relative to controls. When transfected into E. coli, Cr(III)-treated M13mp2 bacteriophage DNA showed a dose-dependent increase in mutation frequency. These results suggest that Cr(III) alters the interaction between the DNA template and the polymerase such that the binding strength of the DNA polymerase is increased and the fidelity of DNA replication is decreased. These interactions may contribute to the mutagenicity of chromium ions in vivo and suggest that Cr(III) can contribute to chromium-mediated carcinogenesis.

Introduction

Chromate is a well-documented human and animal carcinogen. Occupational and environmental exposure to chromium has been widespread, and many studies of the biological effects of chromate compounds have been conducted (1–3). However, because of its complex intracellular metabolism, molecular mechanisms of chromium-induced genotoxicity are not well understood. Chromium genotoxicity and carcinogenesis are complex processes. Chromate ions are actively transported across cell membranes and are reduced intracellularly via reactive Cr(V) and Cr(IV) intermediates to stable Cr(III) species. During this process, oxidative DNA damage and chromium-mediated crosslinks are produced, and point mutations are induced in a number of target genes. However, the mechanisms of chromium-induced mutagenesis are still unclear.

Numerous studies have attempted to determine which intracellular form of chromium or byproduct of chromium reduction is the ultimate carcinogenic and/or mutagenic species (3–5). Redox interactions resulting from chromium reduction (including oxidative base damage) are generally considered the most likely cause of chromate mutagenesis. These processes have been implicated, in part, by increased chromate mutagenesis in A/T-specific Salmonella reversion strains (e.g., TA102) compared with that in G/C specific strains (TA100) (6); by the formation of 8-hydroxyguanine in chromium-treated DNA in vitro (7); and by the formation of active Cr(V) species in vitro (3). Cr(III) is also of interest because it can react with intracellular electrophiles, including nucleic acids, and is the most stable and plentiful form of chromium both in the environment and within the cell after chromium uptake and reduction. As much as 90% of the cellular chromium is present as the trivalent species (8). But Cr(III) does not readily cross cell membranes and is relatively inactive in vivo and in cells in culture (9).

Experiments that have attempted to determine the carcinogenic and mutagenic potential of Cr(III) compounds in vivo yielded negative or ambiguous results (2). Nevertheless, Cr(III) compounds can reach the nucleus of cells within target organs (10) and, once inside the cell, Cr(III) species can be mutagenic (11–13) and genotoxic (13). Recent evidence suggests that Cr(III) species, although previously considered "kinetically inert," can readily bind to nucleic acids in vitro and can even act as redox agents when complexed to a conjugated aromatic ligand (11,14). Cr(III) is also reported to induce a small (2-fold)
increase in misincorporation by DNA polymerases during DNA replication in vitro (15,16). In addition, CrIII ions bound to nuclear DNA increased RNA synthesis in vitro by increasing nonspecific initiation (17–19). This suggests that CrIII might influence the regulation of gene transcription (17).

We have investigated the mechanisms of CrIII genotoxicity in vitro using a DNA replication assay and in vivo by transfection of CrIII-treated DNA into competent E. coli for scoring of survival and mutagenesis. Single-stranded M13 DNA was treated with low concentrations of CrCl3 and excess chromium was removed by gel filtration. DNA replication was then measured on the treated templates. Both the rate of DNA replication and the amount of incorporation per polymerase binding event (processivity) were greatly increased on the chromium-treated template. This process is not polymerase dependent and has been seen with such diverse enzymes as E. coli DNA polymerase I and eukaryotic DNA polymerases α (20) and β. At an optimum concentration of 1 CrIII ion bound per 300 nucleotides, the rate of synthesis by E. coli DNA polymerase I (Klenow) was increased 6-fold relative to the control. When transfected into E. coli, CrIII-treated M13mp2 bacteriophage DNA showed a dose-dependent increase in mutation frequency up to 5-fold above background. These results suggest that CrIII alters the structure of the DNA template resulting in both an increase in the binding strength of the DNA polymerase and a decrease in the fidelity of DNA replication. The combined effect of this template-polymerase association may be the unfaithful bypass of DNA lesions. The CrIII-DNA interactions may thus contribute to both the mutagenicity of chromium ions in vivo and to chromium-mediated carcinogenesis by synergistically enhancing the mutagenicity of any DNA lesions produced during the intracellular reduction of CrVI in vivo.

Experimental Procedures

Materials

M13mp2 and M13mp7 single-stranded bacteriophage DNA was prepared using standard procedures (21). Unlabeled deoxynucleotides were obtained from Sigma Chemical Co. (St. Louis, MO); 32P-labeled nucleotides and 51CrCl3 (20.5 mCi/mmmole) were from New England Nuclear (Boston, MA). The M13 17-mer sequencing primers were synthesized by Bernard Goldschmidt, Department of Environmental Medicine, New York University Medical Center. The T7 Sequenase kit was obtained from the United States Biochemical Corporation (Cleveland, OH). Polymerase I-Klenow fragment (pol I-KF) was obtained from Boehringer Mannheim (Indianapolis, IN). Cloned human DNA polymerase β (22) was a kind gift from Samuel Wilson of the National Cancer Institute. Escherichia coli JM101 was cultured from laboratory stocks maintained on minimal agar plates. Bacto-tryptone, agar, and yeast extract were obtained from Difco laboratories (Detroit, MI). All other chemicals were of molecular biology or DNA grade, and all water was purified through a Milli-Q purification system. All CrCl3 solutions were made fresh daily and diluted as required immediately before use.

Measurement of CrIII Bound to M13mp2 DNA

M13mp2 single-stranded DNA was treated with 51CrCl3 (0.4–50 μM) at 37°C for 30 min in a 50-μL reaction mixture containing 2 μg of DNA, 0.2 mM Tris-HCl (pH 8.0), and 20 μM EDTA. After incubation, the reaction mixtures were spun through Sephadex G-50 spin columns, prepared as described in Maniatis et al. (27), to remove the unbound 51CrIII ions. The amount of 51Cr remaining bound to the DNA was determined by counting the samples in a NaI(T1) scintillation detector coupled to a multichannel analyzer. 3H-TdR-labeled DNA was used in a control reaction to measure DNA recovery.

DNA Replication Using Cr-Treated M13mp2 Primer-Template

M13 17-mer sequencing primer was 5' end-labeled with γ-32P-ATP (3000 Ci/mmmole) and T4 polynucleotide kinase (21). M13mp2 single-stranded DNA was hybridized with a 2-fold molar excess of either radiolabeled or cold primer in a 100-μL reaction mixture containing 20 mM Tris-HCl (pH 7.4), 10 mM MgCl2, 50 mM NaCl, and 10 mM dithiothreitol at 55°C for 10 min, then slowly cooled to room temperature. Chromium-treated templates were prepared by first reacting the DNA template with CrCl3 for 30 min at 37°C and removing the excess chromium by gel filtration, as above. The treated DNA was then hybridized with 2-fold excess primer. Replication was carried out at 37°C for 15 min using 0.2 μg of the modified DNA template and 0.04 units of pol I-KF in a 20-μL reaction mixture containing 40 mM Tris-HCl (pH 7.4), 10 mM β-mercaptoethanol, 5 mM MgCl2, and 50 μM each dNTP (deoxyadenosine triphosphate, deoxyctydine triphosphate, deoxguanosine triphosphate, deoxythymidine triphosphate). The reaction was stopped by the addition of EDTA to a final concentration of 10 mM and the amount of nucleotide incorporation was calculated from the 10% (w/v) trichloroacetic acid-precipitable counts collected on GF/C filters. Each determination was performed in triplicate and the results are presented as the average (± standard error).

Primer Extension Assays

Primer extension was carried out as above using M13mp7 DNA with a 5' end-labeled primer and 0.2 units of cloned DNA polymerase β in the presence of 0, 1, 5, or 10 μM CrCl3. (One unit of polymerase β equals 1 n mole deoxynucleotide monophosphate incorporated into activated calf thymus DNA in 30 min at 37°C.) The primed
DNA was mixed first with the CrCl_3 solution, the extension reactions were initiated by the addition of deoxynucleotide triphosphates and 5 mM MgCl_2, incubated at 37°C for 15 min, and stopped by the addition of 0.5 M EDTA to yield a final concentration of 10 mM. Aliquots were transferred to 1.5-mL microtubes and mixed with loading buffer (99% deionized formamide, 10 mM Na_2EDTA, 10 mM NaOH, and 0.3% each xylene cyanol FF and bromphenol blue) then heated to 96°C for 3 to 4 min and rapidly chilled on ice before loading on an 8% (w/v) polyacrylamide-5 M urea gel which had been prerun for 15 to 30 min. Gel electrophoresis was carried out at 1600 to 1800 V until the dye front was within 2 in. of the bottom. The gel was then transferred to 3M Whatman filter paper and dried for 30 min at 70°C. The dried gel was placed with X-ray film (Kodak XAR-2) and exposed for 1 to 7 days at -70°C with an intensifying screen. Sequencing reactions were carried out using 5' end-labeled primers and templates, prepared as described above, and the "Sequenase" enzyme and buffers according to the manufacturer's instruction with the following modifications: 0.25 mM dATP was added to each of the termination buffers and the labeling mix was diluted 10-fold to increase production of short sequences.

**Mutagenesis Assay**

M13mp2 single-stranded DNA template (0.2 μg) primed with 15-mer was reacted with 0 to 10 μM CrCl_3 for 30 min at 37°C in a total volume of 50 μL in 50 mM Tris-HCl buffer (pH 7.4). The samples were then filtered through Sphadex G-50 spin columns (1000 rpm, 5 min) to remove free CrCl_3. The metal-treated DNA (1–20 ng/sample) was used to transfet 0.2 mL of calcium-treated *E. coli* JM101 competent cells which were prepared using standard procedures (21). The average transfection efficiency of untreated, single-stranded M13mp2 DNA in JM101 was about 400 plaques per nanogram DNA. Aliquots of transfected cells (approximately 10 μL) were plated individually to give approximately 200 to 500 plaques/plate, as described previously (20). The plates were incubated overnight at 37°C, then nonmutant (dark blue) and colorless or light blue (mutant) plaques were counted after 16 to 24 hr at room temperature.

**Results and Discussion**

Both Cr^{III} and Cr^{VI} have been surprisingly refractory in producing mutagenic DNA damage in *vitro* (16,23). Although it is known that chromium produces significant DNA damage and mutagenesis in *vitro*, it is not clear what specific species of chromium ions produce mutagenic DNA damage or what specific type of mutagenic damage is produced by chromium. It has been postulated, for example, that Cr^{VI} intermediates facilitate the production of oxidative damage within the cell and that Cr^{VII}-glutathione conjugates may be involved in DNA-protein crosslinking [see Connett and Wetterhahn (24) for review]. Cr^{III}, on the other hand, has been implicated as a DNA-DNA and DNA-protein crosslinking agent (25,26) but may also be mutagenic directly or by indirect interference with DNA replication fidelity and bypass of DNA lesions. Many different experimental approaches have been used to determine the mutagenic mechanism of Cr^{III} compounds. However, due to the poor ability of Cr^{III} ions to cross the cell membrane in *vitro*, these studies have generally proven negative. In contrast, DNA replication in *vitro* using synthetic polynucleotides and/or φX174 DNA templates in the presence of CrCl_3 or CrCl_2 (which rapidly becomes Cr^{III} in aqueous solution) shows a chromium-dependent increase in the frequency of nucleotide misincorporation (15,16,23). Experiments by Tkeshelashvili et al. (16), for example, have shown that in *vitro* incubation of φX174am3 DNA with CrO_3 produces a 2-fold increase in reversion frequency.

In our preliminary experiments (20), the effects of CrCl_3 on DNA replication in *vitro* were examined in the presence of both template-bound Cr^{III} and free Cr^{III} ions. Under these conditions, low concentrations of Cr^{III} increased, then decreased, DNA polymerase activity and also promoted increased polymerase processivity (20). In subsequent experiments the inhibition of DNA replication by free Cr^{III} ions (21,29) was eliminated by removal of unbound Cr^{III} ions before DNA replication was begun. Chromium binding to DNA is a relatively slow process (data not shown), and a preincubation time of 30 min was chosen for convenience. Cr^{III} binding to DNA under these conditions is dose dependent, as shown in Figure 1. This binding is primarily electrostatic in nature, since 40% or more the bound ions can be displaced by a 15-min high salt wash (0.5 M NaCl) at 37°C, and only 10 to 20% of the chromium is chelatable by 20 mM EDTA (a kinetically slow process) under the same conditions (re-

![Figure 1](https://example.com/image.png)

**Figure 1.** Cr^{III} binding to DNA *in vitro*. A total of 2 μg single-stranded M13mp2 DNA per reaction was incubated with 50CrCl_3 in a total volume of 50 μL TE/50 (0.2 M Tris-HCl, pH 8, 20 μM EDTA) at 37°C for 30 min. Nonbound chromium was then removed by gel filtration through a 1-mL Sephadex G-50 spin column at room temperature. The amount of chromium remaining bound to the DNA template after G-50 chromatography () was determined by using a NaI scintillation counter. DNA recovery determined in a separate experiment using ^4^H-labeled M13 DNA was found to average 85 ± 3%.
treated sequencing jM chromium and that crosslinking processivity assays. The specific primed to extension treated At this concentration ration is approximately chromium ions/template. However, even DNA templates treated with 50 μM CrCl₃ which contain as many as one chromium ion bound for every six nucleotides, still show over a 4-fold increase in nucleotide incorporation relative to the untreated control.

We also studied nucleotide incorporation by primer-extension analysis using a 5'-32P-labeled oligonucleotide-primed M13mp2 template to determine the length of the extended primers on sequencing gels, as shown in Figure 3. This assay allows us to investigate sequence-specific polymerase pausing and termination with the same template and primer used in the incorporation assays. Our previous results suggested that polymerase processivity can be increased by low concentrations of chromium and that either DNA-DNA or DNA-protein crosslinking may also be increased at doses of 5 to 10 μM Cr₃⁺ (20). These results were further confirmed by sequencing gel analysis of replication on chromium-treated templates in the absence of free chromium. After treatment of the template with 1 to 5 μM CrCl₃, the extended primers are much longer than those seen in the presence of chromium, and the increased length is dose dependent. These results suggest that it is the Cr₃⁺ ions that are bound to the DNA template, but not the free chromium, which produces increased poly-

**Figure 2.** Nucleotide incorporation on a chromium-bound template and binding of CrCl₃ to single-stranded M13mp2 DNA. Single-stranded M13 DNA was treated for 30 min at 37°C with 0 to 50 μM CrCl₃ in a total volume of 50 μL, and the unbound chromium was removed by gel exclusion chromatography, as described in the legend to Figure 1. DNA replication was then carried out on 0.2 μg of treated template, and the trichloroacetic acid precipitable nucleotide incorporation was measured (●).

**Figure 3.** Cr₃⁺ increases primer extension by cloned eukaryotic DNA polymerase β on a single-stranded template. M13mp7 was primed with a 5' end-labeled sequencing primer, as described in “Experimental Procedures” and replicated with DNA polymerase β in the presence of CrCl₃ at 37°C for 15 min. The products were analyzed on an 8% sequencing gel adjacent to ddTTP and ddGTP sequencing reactions prepared using the T7 Sequenase kit with the same template and end-labeled primer in the absence of chromium.
Chromium(III)-Mediated Genotoxicity

Polymerase processivity. The results shown here pertain to DNA polymerase β, but similar results have been seen with DNA polymerase α (20) and E. coli polymerase I (20; Snow et al., unpublished observations).

In our previous study, when M13mp2 double-stranded DNA was treated with CrCl₃ (0.5 mM) and transfected into E. coli, the mutation frequency increased only 2-fold above the control (20). More positive results have since been obtained with M13mp2 single-stranded phage. This mutagenesis assay, in contrast to the φX174 reversion assay, can detect a wide variety of mutations within the regulatory and coding sequences of the lacZ gene. When primed single-stranded, M13mp2 DNA templates were pretreated with 1 to 10 μM CrCl₃ and separated from unbound Cr⁢[III] ions by Sephadex G-50 gel filtration prior to transfection into competent JM101 cells, the mutation frequency is increased in a dose-dependent manner up to 5-fold above background (Table 1). The concentration decrease in phage recovery is indicative of CrCl₃ toxicity at concentrations as low as 1 μM. Consistent with reports from other laboratories (2), we have also observed that the CrCl₃ can also induce dose-dependent DNA-DNA crosslinking (20). Such crosslinks are expected to stop DNA replication (28,29) and may correlate with the toxicity of CrCl₃ in the mutagenesis assay with E. coli. The toxicity of Cr⁢[III] in the present study was similar to that reported by Schaaper et al. (33). Since DNA-protein crosslinking is also mediated by Cr⁢[III] in vitro (26) it might be involved in the inhibition of DNA replication observed at higher concentrations of chromium (20).

These observations of Cr⁢[III]-mediated increases in polymerase processivity and mutagenesis are very similar to the effects seen with low (micromolar) concentrations of manganese (MnCl₂). Magnesium ions are usually required as cofactors for DNA polymerase activity. However, MnCl₂ has been shown to substitute for MgCl₂ during DNA replication in vitro (30). At low concentrations, manganese binds preferentially to the phosphate backbone of the DNA template (31,32) and, like chromium, both increases DNA polymerase processivity (33) and decreases fidelity (32,34). Manganese has been shown to be mutagenic in vitro (8,15) and in vivo (35) and can increase polymerase-mediated nucleotide insertion opposite DNA lesions (36). Manganese also increases the production of nontargeted base substitutions and frameshift mutations (37) and nonspecific initiation of RNA transcription (38). Cr⁢[III] has likewise been shown to increase nonspecific initiation by RNA polymerase in vitro (17–19) and in vivo (18) and may act by a similar mechanism.

The increased binding of DNA polymerases to DNA templates by Cr⁢[III] or Mn⁢[II] may specifically increase bypass across DNA-damage or noncoding lesions. Polymerase infidelity during DNA replication past the oxidative damage sites potentially produced during the intracellular reduction of chromium could partially account for the high mutagenic and carcinogenic potential of chromate in vivo. A model for Cr⁢[III]-mediated mutagenesis is shown in Figure 4. Under normal conditions, a replicative DNA polymerase encounters a DNA lesion, pauses, and allows time for DNA repair enzymes to recognize and remove the lesion. The polymerase then continues accurate replication of the template. In the presence of small amounts of Cr⁢[III], however, the polymerase is more tightly bound to the template, and either may not stop at a DNA lesion or may pause too briefly to allow proper recognition of the lesion by DNA repair enzymes. The polymerase may also bind more tightly to the nucleotide precursors, which could promote direct misincorporation. DNA polymerase I in the presence of manganese, for example exhibits lower Kₘ values for both correct and incorrect nucleotide precursors and shows decreased selectivity for the correct base pair (39,40; E. T. Snow, unpublished observations). An increased probability that polymerase will insert an incorrect base opposite a DNA lesion will facilitate by-

Table 1. Mutagenesis of CrCl₃-treated M13 DNA in E. coli.

| CrCl₃ μM | Survival, % | Mutant plaques/total plaques | Mutation frequency, × 10⁵ |
|----------|-------------|------------------------------|------------------------|
| 0        | 100         | 2/22,495                     | 9                      |
| 1        | 82.4        | 16/48,928                    | 33                     |
| 5        | 37.8        | 10/22,403                    | 45                     |
| 10       | 18.1        | 5/10,796                     | 46                     |

*Mutagenesis of the lacZ gene in M13mp2 was determined after transfection of chromium-treated phage DNA into E. coli JM101, as described in "Experimental Procedures." Survival was measured as the total number of plaques per nanogram of transfected DNA relative to the untreated control (400 plaques/ng).

Figure 4. A model for Cr⁢[III]-mediated mutagenesis by polymerase bypass. As shown on the left, 1) a replicative DNA polymerase is expected to pause at sites of DNA damage, which will 2) allow time for DNA repair enzymes to recognize and remove the DNA lesion and 3) promote the subsequent accurate completion of DNA replication. However, in the presence of Cr⁢[III], as shown on the right, 1) the DNA polymerase is more tightly bound to the template, making it more processive and also less faithful. Under these circumstances, when the polymerase encounters a lesion, it is less likely to pause or fall off the template and does not allow recognition of the lesion. Instead, 2) the polymerase is more likely to bypass the lesion and insert an incorrect base opposite the damaged or miscoding base. This could result 3) in the production of a mutation opposite the lesion and, consequently, could also lead to increased tumorigenesis.
pass of the damage site, producing a mutation in the process. Alternatively, CrIII, also like manganese (31), is known to bind preferentially to guanine-containing DNA (41,42). This may result in direct mispairing or may promote oxidation (7) or depurination (23) of the guanine, causing subsequent mispairing of the modified (or missing) base.

The exact mechanisms of CrIII mutagenesis and CrIII-mediated crosslinking or production of oxidative damage in vivo are still far from clear; however, the effects of CrIII, which are shown here to occur at extremely low concentrations, could be significant at the low doses of chromium that are characteristic of environmental exposures to chromate or after limited cellular uptake of environmentally plentiful CrIII.

I thank Li-Sha Xu for her expert technical assistance and Samuel Wilson, who generously provided the cloned DNA polymerase β. The research described in this paper was supported by a National Cancer Institute grant (CA 45664) and a National Institute of Environmental Health Sciences Center grant (ES 00260).

REFERENCES

1. Levis, A. G., and Bianchi, V. Mutagenic and cytogenetic effects of chromium compounds. In: Biological and Environmental Aspects of Chromium (S. Langard, Ed.), Elsevier, Amsterdam, 1982, pp. 171–208.
2. Bianchi, V., Cocoli, E., Lanfranchi, G., Major, F., Marin, G., Montalboli, A., Sponza, G., Tamino, G., Venier, P., Zantedeschi, A., and Levis, A. G. Genetic effects of chromium compounds. Mutat. Res. 117: 279–300 (1983).
3. De Floro, S., and Wetterhahn, K. E. Mechanisms of chromium metabolism and genotoxicity. Life Chem. Rep. 7: 169–244 (1989).
4. Macrae, W. D., Whiting, R. F., and Stich, H. F. Sister chromatid exchanges induced in cultured mammalian cells by chromate. Chem.-Biol. Interact. 26: 281–286 (1979).
5. Whiting, R. F., Stich, H. F., Korostyk, D. J. DNA damage and DNA repair in cultured human cells exposed to chromate. Chem.-Biol. Interact. 26: 267–280 (1979).
6. Petrelli, F. L., and De Floro, S. Interpretations on chromium mutagenicity and carcinogenicity. In: Mutagens in Our Environment (M. Sorsa and H. Vainio, Eds.), Alan R. Liss, Inc., New York, 1982, pp. 453–464.
7. Aiyer, J., Borges, K. M., Floyd, R. A., and Wetterhahn, K. E. Role of chromium(VI) glutathione thiol radical and hydroxy radical intermediates in chromium(VI)-induced DNA damage. Toxicol. Environ. Chem. 22: 135–145 (1989).
8. Leonard, A., and Lauwers, R. C. Carcinogenicity and mutagenicity of chromium. Mutat. Res. 27: 223–239 (1980).
9. Schroeder, H. A., Balassa, J. J., and Tipton, I. H. Abnormal trace metals in man; chromium. J. Chronic Dis. 15: 941–946 (1962).
10. Cupo, D. Y., and Wetterhahn, K. E. Binding of chromium to chromatin and DNA from liver and kidney of rats treated with sodium dichromate and chromium(III) chloride in vivo. Cancer Res. 45: 1146–1151 (1985).
11. Warren, G., Schultz, F., Banerof, D., Bennett, K., Abbott, E. H., and Rogers, S. Mutagenicity of a series of hexacoordinate chromium(III) compounds. Mutat. Res. 90: 111–118 (1981).
12. Elias, Z., Poir, O., Schneider, O., Dianeri, M. C., Terzetti, F., Guedenet, J. C., and Cavelier, C. Cellular uptake, cytotoxicity and mutagenic effects of insoluble chronic oxide in V79 Chinese hamster cells. Mutat. Res. 196: 159–170 (1986).
13. Nakamura, K., Yoshikawa, K., Sayato, Y., and Kurata, H. Comparative studies of chromosomal aberration and mutagenicity of trivalent and hexavalent chromium. Mutat. Res. 58: 175–181 (1978).
14. Sugden, K. D., Burris, R. B., and Rogers, S. J. An oxygen dependence in chromium mutagenesis. Mutat. Res. 244: 239–244 (1990).
15. Sirover, M. A., and Loeb, L. A. On the fidelity of DNA replication: effect of metal activators during synthesis with avian myeloblastosis virus DNA polymerase. J. Biol. Chem. 252: 3605–3610 (1977).
16. Köpf, K., Shearman, C. W., Zakour, R. A., Koplitz, R. M., and Loeb, L. A. Effect of arsenic, selenium, and chromium on the fidelity of DNA synthesis. Cancer Res. 40: 2455–2460 (1980).
17. Okada, S., Ohba, H., and Tanigawa, M. Alterations in ribonuclease A activity in mice treated with chromium(III). J. Inorg. Biochem. 15: 223–231 (1981).
18. Ohba, H., Suzuki, M., and Ohba, H. Enhancement of ribonuclease A activity in chromium(III) in mouse liver. J. Inorg. Biochem. 19: 95–103 (1985).
19. Ohba, H., Suketa, Y., and Okada, S. Enhancement of ribonuclease A activity in chromium(III)-bound chromatin. J. Inorg. Biochem. 27: 179–189 (1986).
20. Snow, E. T., and Xu, L. S. Effects of chromium(III) on DNA replication in vitro. Biol. Trace Element Res. 21: 115–117 (1987).
21. Maniatis, T., Fritsch, E. F., and Sambrook, J. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1982.
22. Wilson, S., Abbott, J., and Widen, S. Progress toward molecular biology of DNA polymerase β. Biochim. Biophys. Acta 949: 149–157 (1988).
23. Schaaper, R. M., Koplitz, R. M., Tkeshelashvili, L. K., and Loeb, L. A. Metal-induced lethality and mutagenesis: possible role of apurinic intermediates. Mutat. Res. 177: 179–188 (1987).
24. Connott, P. H., and Wetterhahn, K. E. Metabolism of the carcinogenic chromium by cellular constituents. Struct. Bond. 54: 94–124 (1985).
25. Forncast, A. J., Jr., Seres, D. S., Lechner, J. P., and Harris, C. C. DNA-protein cross-linking by chromium salts. Chem.-Biol. Interact. 36: 345–354 (1981).
26. Cohen, M. D., Miller, C. A., Xu, L. S., Snow, E. T., and Costa, M. A. Blotting method for monitoring the formation of chemically-induced DNA-protein complexes. Anal. Biochem. 186: 1–7 (1990).
27. Nishio, A., and Uyeki, E. M. Inhibition of DNA synthesis by chromium compounds. J. Toxicol. Environ. Health 15: 237–244 (1985).
28. Bernardes, F., and Holler, E. Effects of coordination of diaminoplatinum(II) with DNA on the activities of Escherichia coli DNA polymerase I. Biochemistry 27: 6398–6402 (1988).
29. Villani, G., Hubscher, U., and Butot, J. L. Site of termination of in vitro DNA synthesis on cis-diaminedichloroplatinum(II) treated single-stranded DNA: a comparison between E. coli DNA polymerase I and eucaryotic DNA polymerase α. Nucl. Acids Res. 16: 4407–4418 (1988).
30. Sirover, M. J., Dubé, D. K., and Loeb, L. A. On the fidelity of DNA replication: metal activation of Escherichia coli DNA polymerase I. J. Biol. Chem. 264: 102–111 (1979).
31. van Steenkink, K., Campagnari, F., and Merlini, M. Interaction of Mn²⁺ with DNA as studied by proton-relaxation enhancement of solvent water. Biopolymers 29: 915–923 (1981).
32. Beckman, R. A., Miledman, A. S., and Loeb, L. A. On the fidelity of DNA replication: manganese mutagenesis in vitro. Biochemistry 24: 5810–5817 (1985).
33. Hohn, K. T., and Grosse, F. Procesivity of DNA polymerase α-pimase complex from calf thymus. Biochemistry 26: 2870–2878 (1987).
34. Hilebrand, G. G., and Beattie, K. T. Template-dependent variation in the relative fidelity of DNA polymerase I of Escherichia coli in the presence of Mg²⁺ versus Mn²⁺. Nucl. Acids Res. 12: 3173–3183 (1984).
35. Zakour, R. A., and Glickman, B. W. Metal-induced mutagenesis in vitro of the lacI gene of Escherichia coli. Mutat. Res. 126: 9–18 (1984).
36. Rabin, S. D., and Strauss, C. S. A role for DNA polymerase in the specificity of nucleotide incorporation opposite N-acetyl-2-aminofluorour ides. J. Mol. Biol. 178: 569–594 (1984).
37. Tindall, K. F., Warren, G. R., and Skaar, P. D. Metal ion effects in microbial sequencing systems. Mutat. Res. 53: 90–91 (1978).
38. Niigyo, S. K., Feldman, R. P., and Hoffman, D. J. Effect of several metal ions in misincorporation during transcription. Toxicology 22: 9–21 (1981).
39. Goodman, M. F., Keener, S., Guidotti, S., and Branscomb, E. W. On the enzymatic basis for mutagenesis by manganese. J. Biol. Chem. 258: 3469–3475 (1983).
40. El-Deiry, W. S., Downey, K. M., and So, A. G. Molecular mechanisms of manganese mutagenesis. Proc. Natl. Acad. Sci. U.S. 81: 7378–7382 (1984).
41. Tsapakos, M. J., and Wetterhahn, K. E. The interaction of chromium with nucleic acids. Chem.-Biol. Interact. 46: 265–277 (1983).
42. Wolf, T., Kasemann, R., and Ottenwalder, H. Molecular interaction of different chromium species with nucleotides and nucleic acids. Carcinogenesis 10: 655–659 (1989).